Table 2 Patient characteristics
Patients | ||
|---|---|---|
Characteristic | No. | % |
All patients | 140 | |
Sex | ||
Male | 108 | 77 |
Female | 32 | 23 |
Age (years) | ||
Median | 65 | |
Range | 18–87 | |
ECOG performance status | ||
0 | 70 | 50 |
1 | 62 | 44 |
2 | 8 | 6 |
Metastatic site | ||
Lymph nodes | 87 | 62 |
Peritoneum | 43 | 31 |
Liver | 43 | 31 |
Lung | 8 | 6 |
Other | 9 | 6 |
Histological type | ||
Intestinal | 60 | 43 |
Diffuse | 80 | 57 |
First-line chemotherapy regimen | (Response rate a (95% CI)) | |
S-1 | 69 | 34.8 (23.7–47.2) |
Cisplatin+S-1 | 14 | 35.7 (12.8–64.9) |
Cisplatin+irinotecan | 29 | 44.8 (26.5–64.3) |
5-FU | 23 | 4.3 (0.1–22.0) |
5-FU+methotrexate | 2 | 0 |
Paclitaxel | 2 | 50.0 (1.3–98.7) |
Uracil/ftorafur (UFT®) | 1 | 0 |
